Key result
Direct oral anticoagulants are the preferred initial therapy for most venous thromboembolism patients due to their ease of use and superior safety profile compared to vitamin K antagonists.
Why the study?
Anticoagulation in venous thromboembolism management requires a tailored approach balancing recurrence risk against bleeding complications, with special considerations needed for specific populations.
Direct oral anticoagulants are the preferred initial therapy for most VTE patients, while emerging factor XI and XII inhibitors show promise in reducing bleeding risk.
Anticoagulation in venous thromboembolism (VTE) management requires a tailored approach that balances the risk of recurrence with the potential for bleeding complications. Direct oral anticoagulants have become the preferred initial therapy for most patients due to their ease of use and superior safety profile compared to vitamin K antagonists. Special considerations, however, are necessary for certain populations. Patients with renal impairment, cancer, or recurrent VTE may require alternative therapies or extended anticoagulation. Emerging anticoagulants targeting factor XI and XII show promise in reducing bleeding risk while preventing thrombosis.
No takes yet. Share an insight, caveat, or question.
Anjum et al. (2025) conducted a review in Venous thromboembolism. Anticoagulation therapy was evaluated. Direct oral anticoagulants are the preferred initial therapy for most venous thromboembolism patients due to their ease of use and superior safety profile compared to vitamin K antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: